Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

My-K Labs' founder Kun Chae Bae

Executive Summary

Pleaded guilty on April 20 in Baltimore Federal Court to one count of making illegal payments totaling $30,000 to former FDA Division of Generic Drugs Branch Chief Charles Chang, and to one count of providing a $500 gift certificate for a department store, a video cassette recorder, and two trips to Chicago to Joseph Maselli, a buyer for the Medical Directorate at the Defense Personnel Support Center in Philadelphia. Bae was charged on April 12 to one count of interstate travel in aid of racketeering in connection with one payment of $10,000 to Chang ("The Pink Sheet" April 16, T&G-1). Bae faces maximum penalties of five years incarceration and a $250,000 fine on the racketeering charge and two years in jail and a 250,000 fine on the gratuities charge.

You may also be interested in...



Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative

Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS017302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel